Philosophy Capital Management LLC Grows Stake in Solventum Corporation $SOLV

Key Points

• Philosophy Capital Management LLC increased its stake in Solventum Corporation ($SOLV) by 49.2% in the first quarter, owning approximately $23.6 million worth of the company's stock.
• Several institutional investors have also strengthened their positions in Solventum, with some increasing holdings by over 376% during the same period.
• Analysts have generally upgraded their ratings for Solventum, with one firm setting a target price of $103, while the stock currently has a consensus rating of "Hold" with an average target of $85.75.

Philosophy Capital Management LLC raised its position in Solventum Corporation (NYSE:SOLV - Free Report) by 49.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 310,066 shares of the company's stock after buying an additional 102,286 shares during the period. Solventum accounts for 1.7% of Philosophy Capital Management LLC's investment portfolio, making the stock its 13th biggest holding. Philosophy Capital Management LLC owned 0.18% of Solventum worth $23,577,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SOLV. Banque Transatlantique SA lifted its holdings in Solventum by 9,219.8% during the first quarter. Banque Transatlantique SA now owns 59,274 shares of the company's stock worth $4,165,000 after acquiring an additional 58,638 shares during the period. Concurrent Investment Advisors LLC purchased a new stake in Solventum during the first quarter worth about $216,000. Bessemer Group Inc. raised its position in Solventum by 17.1% in the first quarter. Bessemer Group Inc. now owns 1,963 shares of the company's stock worth $150,000 after acquiring an additional 287 shares during the period. Comerica Bank boosted its stake in Solventum by 39.7% in the first quarter. Comerica Bank now owns 77,725 shares of the company's stock valued at $5,910,000 after acquiring an additional 22,079 shares during the last quarter. Finally, CW Advisors LLC bought a new position in Solventum during the first quarter valued at $312,000.

Solventum Stock Down 2.2%

Shares of NYSE:SOLV traded down $1.66 during trading on Tuesday, reaching $72.94. 930,094 shares of the stock traded hands, compared to its average volume of 1,280,160. The stock has a market cap of $12.65 billion, a P/E ratio of 13.35, a price-to-earnings-growth ratio of 3.05 and a beta of 0.53. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The stock has a 50-day moving average of $73.50 and a two-hundred day moving average of $72.76. Solventum Corporation has a 52-week low of $60.70 and a 52-week high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same period last year, the business posted $1.56 EPS. The company's revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, sell-side analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on SOLV. Wells Fargo & Company raised their price target on shares of Solventum from $75.00 to $79.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Piper Sandler restated an "overweight" rating and set a $94.00 target price (up from $87.00) on shares of Solventum in a report on Friday, August 8th. Wall Street Zen cut shares of Solventum from a "strong-buy" rating to a "buy" rating in a research report on Tuesday. Argus upgraded Solventum from a "hold" rating to a "buy" rating and set a $90.00 target price for the company in a report on Tuesday, July 1st. Finally, KeyCorp initiated coverage on shares of Solventum in a report on Friday, June 6th. They issued a "sector weight" rating for the company. Four analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $85.75.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.